RESUMEN

A new immunomodulatory lead Cumaside that is a complex of monosulfated triterpene glycosides from the sea cucumber Cucumaria japonica and cholesterol possesses significantly less cytotoxic activity against sea urchin embryos and Ehrlich carcinoma cells than the corresponding glycosides. Nevertheless Cumaside has an antitumor activity against different forms of experimental mouse Ehrlich carcinoma in vivo both independently and in combination with cytostatics. The highest effect occurs at a treatment once a day for 7 days before the tumor inoculation followed by Cumaside treatment once a day for 7 days. Prophylactic treatment with Cumaside and subsequent therapeutic application of 5-fluorouracil suppressed the tumor growth by 43%.

Asunto(s)

Antineoplásicos/uso terapéutico , Carcinoma de Ehrlich/tratamiento farmacológico , Colesterol/análogos & derivados , Glicósidos/uso terapéutico , Factores Inmunológicos/uso terapéutico , Triterpenos/uso terapéutico , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Línea Celular Tumoral , Colesterol/química , Colesterol/uso terapéutico , Femenino , Fluorouracilo/uso terapéutico , Glicósidos/química , Factores Inmunológicos/química , Factores Inmunológicos/farmacología , Masculino , Ratones , Saponinas/uso terapéutico , Triterpenos/química